Company Spotlight: DeepHealth ProstateAI - Standardizing Prostate MRI Detection

This episode unpacks the FDA 510(k) summary for DeepHealth ProstateAI, a radiological software device developed by Quantib BV. We explore how the deep learning tool assists physicians in detecting and characterizing prostate cancer lesions, examine its performance metrics in a multi-reader study, and discuss the clinical implications of its specific workflow requirements.

Key points

• DeepHealth ProstateAI is cleared as a concurrent reading aid for physicians assessing bi-parametric prostate MRIs in patients aged 40 years and older.
• Unlike its predicate device, it requires a separate binary mask containing the prostate gland segmentation to function.
• The software categorizes identified lesions into low, moderate, or high suspicion levels, which corresponded to confirmed cancer rates of 10%, 46%, and 86% in the validation cohort.
• Clinical testing involved a retrospective reader study where AI assistance improved the case-level detection AUC-LROC score from 0.626 to 0.724.
• The FDA cleared the device based on substantial equivalence to the ProstatID software, despite differences in underlying algorithms and output formats.

Source: FDA 510(k) summary K253682: DeepHealth ProstateAI (Quantib) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Quantib · Product: DeepHealth ProstateAI · FDA 510(k) K253682

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-deephealth-prostateai-standardizing-prostate-mri-det-3faaa8